Company: NCEL
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065783
Chunk: 447

Company: NewcelX Ltd.
Filing Date: 2025-07-18
Form: F-4/A
Chunk 447
---
 yet occurred. The Company uses and intends to further use the net proceeds from the offering for working capital and general corporate purposes. On March27, 2025, we entered into a securities purchase agreement, or the March 2025 SPA, with three accredited investors. Pursuant to the terms of the March 2025 SPA, the Company agreed to issue and sell to the investors, in a private placement offering, or the March 2025 Offering, 1,212,122 NLS Preferred Shares with a conversion price of $1.65 per share, as well as warrants to purchase 787,880 NLS Common Shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $2million. The March 2025 Offering initially closed on March28, 2025. Pursuant to 235 the terms of the March 2025 SPA, the investors may purchase up to $1million of additional NLS Preferred Shares on identical terms as the initial closing, subject to the Company obtaining shareholder approval. On June26, 2025, we executed an amendment, or the Amendment, to the March 2025 SPA. Pursuant to the terms of the Amendment, the investors agreed to purchase PPCs in lieu of NLS Preferred Shares with the same rights and privileges as the NLS Preferred Shares. Pursuant to the terms of the Amendment, the Company agreed to issue 606,061 PPCs, as well as warrants to purchase 393,939 NLS Common Shares at an exercise price of $1.80 per share, for aggregate gross proceeds of $1million. The second closing occurred on June27, 2025. In addition, on June26, 2025, the Company and Alpha entered into a side letter pursuant to which the Company agreed to issue Alpha pre -fundedwarrants to purchase 485,000 NLS Common Shares in lieu of the Company’s prior agreement, contained in the March 2025 SPA, to issue Alpha 435,000 NLS Preferred Shares (or their equivalent) to compensate Alpha for certain price protection issuances and registration obligations. The initial closing of the March 2025 Offering resulted in gross proceeds to the Company of to $2million. The Company intends to use the net proceeds from the March 2025 Offering for working capital and general corporate purposes, including for expenses relating to the Merger. Further, on March31, 2025, the Company entered into a common shares purchase agreement with Alpha, or the Facility